Are You Looking for a Top Momentum Pick? Why LifeStance Health Group (LFST) is a Great Choice
Does LifeStance Health Group (LFST) have what it takes to be a top stock pick for momentum investors? Let's find out.
LFST - LifeStance Health Group, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$10.25
DETAILS
HIGH:
$11.00
LOW:
$9.00
MEDIAN:
$10.50
CONSENSUS:
$10.25
DOWNSIDE:
2.29%
Stock News
LifeStance Health (LFST) Upgraded to Strong Buy: Here's What You Should Know
LifeStance Health (LFST) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
4 Outpatient Home Health Stocks Benefiting From Industry Trends
An aging population and rising telehealth and AI adoption boost demand in the Zacks Medical - Outpatient and Home Healthcare industry. DGX, DVA, LFST and AVAH stand to benefit.
Wall Street Analysts Predict a 37.26% Upside in LifeStance Health (LFST): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 37.3% in LifeStance Health (LFST). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Bears are Losing Control Over LifeStance Health (LFST), Here's Why It's a 'Buy' Now
After losing some value lately, a hammer chart pattern has been formed for LifeStance Health (LFST), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
LifeStance Health Group, Inc. (LFST) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
LifeStance Health Group, Inc. (LFST) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Earnings Estimates Rising for LifeStance Health (LFST): Will It Gain?
LifeStance Health Group (LFST) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
LifeStance Health Group (LFST) is a Great Momentum Stock: Should You Buy?
Does LifeStance Health Group (LFST) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts See a 31.02% Upside in LifeStance Health (LFST): Can the Stock Really Move This High?
The consensus price target hints at a 31% upside potential for LifeStance Health (LFST). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
LifeStance Health Group Q1 Earnings Call Highlights
LifeStance Health Group NASDAQ: LFST reported first-quarter 2026 results that management said exceeded expectations and prompted the company to raise full-year guidance across its key metrics. On the company's earnings call, CEO Dave Bourdon highlighted what he described as an “exceptional start to the year,” pointing to revenue growth of more than 21% and adjusted EBITDA topping $50 million.
LifeStance Health Group Announces Pricing of Secondary Public Offering
SCOTTSDALE, Ariz. , May 07, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. ("LifeStance" or the "Company") (Nasdaq: LFST), one of the nation's largest providers of virtual and in-person outpatient mental health care, today announced the pricing of a secondary underwritten public offering of 35,000,000 shares of LifeStance's common stock, par value $0.
LifeStance Health Group Announces Pricing of Secondary Public Offering
SCOTTSDALE, Ariz., May 07, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (Nasdaq: LFST), one of the nation's largest providers of virtual and in-person outpatient mental health care, today announced the pricing of a secondary underwritten public offering of 35,000,000 shares of LifeStance's common stock, par value $0.01 per share (the “Common Stock”) at a public offering price of $8.15 per share, pursuant to a shelf registration statement filed with the Securities and Exchange Commission (the “SEC”) from certain stockholders of the Company (the “Selling Stockholders”). The Selling Stockholders will receive all of the proceeds from the offering. The Company is not selling any shares of Common Stock in the offering and will not receive any proceeds from the offering.
Why LifeStance Health Group Zoomed 20% Higher Today
This was strongly evidenced by its 21% revenue increase in the first quarter. Its profitability rocketed even higher.
LifeStance Health Group Announces Launch of Secondary Public Offering
SCOTTSDALE, Ariz., May 07, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (Nasdaq: LFST), one of the nation's largest providers of virtual and in-person outpatient mental health care, today announced that pursuant to a shelf registration statement filed with the Securities and Exchange Commission (the “SEC”), certain stockholders of the Company (the “Selling Stockholders”) intend to offer 35,000,000 shares of LifeStance's common stock, par value $0.01 per share (the “Common Stock”). The Selling Stockholders will receive all of the proceeds from the offering. The Company is not selling any shares of Common Stock in the offering and will not receive any proceeds from the offering.
LifeStance Health Group, Inc. (LFST) Q1 2026 Earnings Call Transcript
LifeStance Health Group, Inc. (LFST) Q1 2026 Earnings Call Transcript
LifeStance Reports First Quarter 2026 Results
SCOTTSDALE, Ariz., May 07, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced financial results for the first quarter ended March 31, 2026.
LifeStance to Present at Upcoming Investor Conferences
SCOTTSDALE, Ariz., April 29, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced that management will present at the following upcoming investor conferences.
A LifeStance Health Insider Sold Nearly 70,000 Shares. Here's What That Means for Investors.
Specializing in outpatient mental health services, this hybrid care provider reported a notable insider sale in its latest SEC filing.
New Strong Buy Stocks for April 28th
APA, MPC, PSX, LFST and GLPEY have been added to the Zacks Rank #1 (Strong Buy) List on April 28th, 2026.
Chemed (NYSE:CHE) & LifeStance Health Group (NASDAQ:LFST) Financial Comparison
Chemed (NYSE: CHE - Get Free Report) and LifeStance Health Group (NASDAQ: LFST - Get Free Report) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability. Institutional and Insider Ownership 95.9% of Chemed
Price Targets
Goldman Sachs Starts Lifestance Health Group (LFST) at Neutral
$9.00
(was $7.64)
Scott Fidel
·
Goldman Sachs
LifeStance price target raised to $11 from $10 at Canaccord
$11.00
(was $8.85)
Canaccord Genuity
LifeStance price target raised to $10 from $8 at BMO Capital
$10.00
(was $7.41)
BMO Capital
LifeStance price target raised to $11 from $10 at BTIG
$11.00
(was $7.07)
David Larsen
·
BTIG
LifeStance price target raised to $8.50 from $6.50 at KeyBanc
$8.50
(was $7.30)
Steve Dechert
·
KeyBanc
LifeStance price target raised to $9 from $8 at Canaccord
$9.00
(was $7.30)
Richard Close
·
Canaccord Genuity
LifeStance price target raised to $10 from $9 at BTIG
$10.00
(was $6.77)
BTIG
LifeStance initiated with an Overweight at Barclays
$8.00
(was $6.41)
Peter Warendorf
·
Barclays
LifeStance upgraded to Buy from Neutral at UBS
$8.50
(was $6.06)
Kevin Caliendo
·
UBS